Intercept Pharmaceuticals (ICPT) Reports Additional Positive OCA Data In Patients With Bile Acid Diarrhea At Digestive Disease Week
5/7/2014 9:15:46 AM
NEW YORK, May 6, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept) today announced new OBADIAH trial results showing potential clinical benefits of obeticholic acid (OCA) for patients with bile acid diarrhea. OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR) in development for primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH) and other liver and intestinal diseases, including bile acid diarrhea. The new OBADIAH trial results were presented today at Digestive Disease Week® 2014 (DDW) in Chicago. OBADIAH is an investigator-initiated and sponsored open label Phase 2 trial conducted by Professor Julian Walters and colleagues at Imperial College, London in the United Kingdom. The trial evaluated once daily administration of 25 mg OCA for two weeks in 32 patients with diarrhea. Initial results from the OBADIAH trial in primary bile acid diarrhea were presented in 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by